Equities

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc

Actions
  • Price (EUR)0.975
  • Today's Change0.075 / 8.33%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

Lineage Cell Therapeutics Inc (BT3:DUS) set a new 52-week low during today's trading session when it reached 0.90. Over this period, the share price is down -13.72%.
52-week range
Today
0.90May 22 20241.22Apr 15 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open0.90
High0.975
Low0.90
Bid0.95
Offer1.00
Previous close0.90
Average volume2.34k
Shares outstanding188.82m
Free float188.01m
P/E (TTM)--
Market cap190.71m USD
EPS (TTM)-0.1344
USD
Data delayed at least 15 minutes, as of May 22 2024 18:31 BST.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.